Pheochromocytoma: When to search a germline defect?

Area of Science:

• Endocrinology
• Oncology
• Genetics

Background:

• Pheochromocytomas and paragangliomas (PPGL) are rare tumors with a significant, previously underestimated, hereditary component.
• Understanding the genetic basis of PPGL has evolved, revealing a higher prevalence of germline mutations than previously recognized.

Purpose of the Study:

• To address the evolving question of whether germline defects should be investigated in patients diagnosed with PPGL.
• To highlight the increased identification of PPGL susceptibility genes and the implications for clinical practice.

Main Methods:

• Review of advances in understanding PPGL genetics.
• Application of next-generation sequencing (NGS) for simultaneous genotyping of multiple susceptibility genes.
• Analysis of current guidelines recommending genetic testing for PPGL patients.

Main Results:

• Approximately 40% of PPGL patients carry a germline mutation in a PPGL susceptibility gene, a significant increase from earlier estimates (10%).
• Over 15 susceptibility genes for PPGL have been identified, establishing it as a highly heritable neuroendocrine tumor.
• Genetic testing identifies patients requiring specific inherited disease follow-up and enables predictive testing for at-risk relatives.

Conclusions:

• Genetic testing is now a crucial component of the initial workup for pheochromocytoma and paraganglioma patients.
• The identification of germline mutations facilitates tailored patient management and family screening.
• Future developments in precision medicine for PPGL are anticipated, based on tumor molecular profiles.